CD200 and cancer: Interestingly, while expression of CD200 rapidly decreases using treatment with the MEK inhibitor (UO126), resistance develops to this treatment, consistent with the idea of alternate (MEK-independent) pathways of regulation of CD200 expression (transcriptional and/or translational) in human cancer cells.